LY4355756

LY4355756 is an investigational **small molecule GIP receptor (GIPR) antagonist** developed by **Eli Lilly and Company**. It is currently being evaluated in **Phase 1** clinical trials for the treatment of **obesity** and other metabolic disorders. The drug is designed for **oral** administration, representing a next-generation approach to metabolic disease management that aims to provide a more convenient alternative to injectable incretin-based therapies. While GIP (gastric inhibitory polypeptide) is traditionally known as an insulinotropic hormone, pharmacological antagonism of its receptor has emerged as a potent strategy for weight loss, particularly when combined with GLP-1 receptor agonism. LY4355756 is being studied as a monotherapy in early-stage trials to establish its safety, tolerability, and pharmacokinetic profile in healthy participants.